Get access

Severe chronic refractory immune thrombocytopenic purpura during childhood: A survey of physician management

Authors

  • Cindy E. Neunert MD,

    Corresponding author
    1. Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
    2. Center for Cancer and Blood Disorders, Children's Medical Center Dallas, Dallas, Texas
    • Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75390-9063.
    Search for more papers by this author
  • Brianna C. Bright MA,

    1. Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
    Search for more papers by this author
  • George R. Buchanan MD

    1. Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
    2. Center for Cancer and Blood Disorders, Children's Medical Center Dallas, Dallas, Texas
    Search for more papers by this author

Abstract

Background

Physician attitudes regarding management of children with severe chronic immune thrombocytopenic purpura (ITP) have not been recently characterized.

Procedure

We designed a survey of members of the American Society of Pediatric Hematology-Oncology (ASPHO) that described a 5-year-old female with ITP for 1 year who was unresponsive to steroids, IVIG, and anti-D immune globulin and having frequent epistaxis causing interference with her daily activities. A 13-item questionnaire evaluated physician decision-making in this setting.

Results

Two hundred and ninety-seven surveys (35% response rate) were returned, and 295 were evaluable. Thirty-three percent of respondents stated that they would recommend splenectomy for such a child. Of those who would not recommend splenectomy, 67% reported that they would instead treat with rituximab. If initial drug therapy failed, 47% would proceed with splenectomy. Those who reported treating with rituximab initially were more likely to recommend splenectomy following failure than those who preferred other drug therapy (P < 0.0001).

Conclusions

Physician management of patients with chronic ITP is diverse. With the advent of new treatments such as rituximab and thrombopoetic agents it is critically important to compare their cost, adverse effects and efficacy with splenectomy in order to optimally guide treatment practices. Pediatr Blood Cancer 2008;51:513–516. © 2008 Wiley-Liss, Inc.

Ancillary